Tandem cycles pay-go transition to US$265m raise
Tandem Diabetes Care tapped into renewed investor enthusiasm for its business transition by raising an upsized US$265m late on Tuesday from the sale of a six-year convertible bond, marking a return for the serial issuer.
Goldman Sachs and Barclays revised talk on the offering late in the bookbuild to a zero-percent coupon, up 35%–40% from launch talk of a zero-percent fixed coupon and 30%–35% conversion, while keeping the offer size at US$200m. They upsized to US$265m priced at zero-percent, up 37.5%.
“This is a small deal from a company with a good profile to issue a convertible bond and a rational use of proceeds,” said one convert arb fund manager. “The deal did launch on the cheaper side.”
In marketing the deal, the banks guided accounts toward a credit spread and implied vol of SOFR+250bp and 50.
While Tandem has yet to turn a profit, the company’s transition to a pay-as-you-go approach to selling its insulin pumps through pharmacies, rather than having consumers foot the hefty bill upfront, is a positive step forward.
Since announcing the transition late last week alongside fourth-quarter earnings, Tandem’s shares spiked roughly 50% ahead of the CB launch to US$28.26 – while marketing the CB, they fell 4.8% to US$26.90.
To lock in that benefit, Tandem spent US$13.5m of CB proceeds on a capped call to offset dilution up to a share price of US$47.08, a 75% premium to reference. In addition to the new CB, the company has a US$316.25m 1.5% CB that is convertible at US$34.56 and matures in March 2029.
Including a US$70m–$80m “headwind” from the lower-cost pay-as-you-go model, Tandem expects US sales in 2026 of US$730m–$745m. Another US$335m–$340m of sales will come from international markets, after ramping up direct-to-consumer operations in Switzerland, the UK and Austria in Q1 2026.
About 15% of US sales by year-end are expected to come through pharmacies, from 5% currently, with a long-term goal of more than 70%.
Tandem is betting that by lowering price more consumers will try its insulin pumps, generating higher, more predictable revenue from consumables over time despite reducing revenue in the short term.
Insulet uses a similar subscription-based model to sell its insulin pumps.